Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 2, 1998, Pages 945-951

  Murphy, Natalie P ^a   Pratico, Domenico ^b   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; N [N [N (4 AMIDINOBENZOYL)ALANYL]ASPARTYL] 3 PHENYLALANINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DOG; DOSE RESPONSE; DRUG RECEPTOR BINDING; HEART MUSCLE REPERFUSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; THROMBOCYTE AGGREGATION INHIBITION;

ACETATES; ANIMALS; BINDING SITES; BLOOD PLATELETS; CORONARY THROMBOSIS; DOGS; FIBRINOLYTIC AGENTS; HEMORRHAGE; OLIGOPEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REPERFUSION INJURY; THROMBOXANE B2; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE;

EID: 0032411217     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Abrams CS, Ruggeri ZM, Taub R, Hoxie JA, Nagaswami C, Weisel JW and Shattil SJ (1992) Anti-idiotypic antibodies against an antibody to the platelet glycoprotein (GP) IIb/IIIa complex mimic GP IIb/IIIa by recognizing fibrinogen. J Biol Chem 267:2775-2785.
2. Bergsdorf N, Nilsson T and Wailen P (1983) An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 30:740-744.
3. Cohen I, Burk DL and White JG (1989) The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb/IIIa complex on the development of clot tension. Blood 73:1880-1887.
4. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, et al. (1991) Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 614:193-213.
5. Fitzgerald DJ, Catella F, Roy L and FitzGerald GA (1988) Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 77:142-50.
6. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 86:7585-7589.
7. Fitzgerald DJ, Hanson M and FitzGerald GA (1991) Systemic lysis protects against the effects of platelet activation during coronary thrombolysis. J Clin Invest 88;1589-1595.
8. 2 modulates the response to tissue-type plasminogen activator in vivo. Cire Res 65:83-94.
9. Fox JE, Lipfert L, Clark EA, Reynolds CC, Austin CD and Brugge JS (1993) On the role of the platelet membrane skeleton in mediating signal transduction. Association of GP IIb IIIa, pp60c-src, pp62c-yes, and the p21ras GTPase-activating protein with the membrane skeleton. J Biol Chem 268:25973-25984.
10. Frelinger III AL, Du XP, Plow EF and Ginsberg MH (1991) Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb IIIa) alter receptor affinity, specificity and function. J Biol Chem 266:17106-17111.
11. George JN, Caen JP and Nurden AT (1990) Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 75:1383-1395.
12. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA and Collen D (1988) Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 77:670-677.
13. 2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 77:678-684.
14. ISIS-2 (Second international study of infarct survival collaborative group) (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2:349-650.
15. Jennings LK, Fitzgerald DJ and White M (1993) An active conformation of platelet GP IIb/IIIa that binds to fibrin(ogen) does not mediate clot retraction. Blood 82:829 (Abstract).
16. Kerins DM, Roy L, FitzGerald GA and Fitzgerald DJ (1989) Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 80:1718-1725.
17. Kouns WC, Kirchlofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK and Steiner B (1992) Reversible conformational changes induced in glycoprotein IIb IIIa by a potent and selective peptidomimetic inhibitor. Blood 80:2539-2547.
18. Kouns WC, Wall CD, White MM, Fox CF and Jennings LK (1990) A conformation-dependent epitope of human platelet glycoprotein IIIa. J Biol Chem 265:20594-20601.
19. Kunitada S, FitzGerald G and Fitzgerald D (1992) Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 79:1420-1427.
20. Marguerie GA, Plow EF and Edgington TS (1979) Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 254:5357-5363.
21. Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J and Lucchesi BR (1990) Antiplatelet antibody [7E3F(ab′)2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 81:617-627.
22. Nowak J, Murray JJ, Oates JA and FitzGerald GA (1987) Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 76:6-14.
23. FAK in platelets requires coordinated signaling through integrin and agonist receptors. J Biol Chem 269: 14738-14745.
24. Steiner B, Haering P, Jennings L and Kouns WC (1993) Five independent neoepitopes on GP IIb IIIa are differentially exposed by two potent peptidomimetic platelet inhibitors. Thromb Haemost 69:782 (Abstract).
25. Stephens G, O'Luanaigh N, Reilly D, Horriott P, Walker B, Fitzgerald D, Moran N. A sequence within the cytoplasmic tail of GP IIb independently activates platelet aggregation and thromboxane synthesis. J Biol Chem (in press, 1998).
26. Torti M, Ramaschi G, Sinigaglia F, Lapetina EG and Balduini C (1994) Glycoprotein IIb/IIIa and the translocation of Rap2B to the platelet cytoskeleton. Proc Natl Acad Sci USA 4239-43.
27. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ and Collen D (1988) Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 81:1284-91.